Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T16:17:48.359Z.
Calculation as of: 2026-10-06T16:17:48.359Z.
Quote observation: 2026-10-06T16:15:19.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 619c5482a9d59cec4bb20d2c4447c35828cdfaa1e6076b938dd954a9c5cde0ad
PE RATIO
N/A
Market Cap
$1.99B
PE Ratio
14.92
TTM Avg
29.48
3Y Avg
184.64
5Y Avg
184.64
Market Cap
$2.02B
PE Ratio
6.87
TTM Avg
15.39
3Y Avg
40.25
5Y Avg
40.25
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | $2.00B | N/A | N/A | N/A | N/A |
| Inspire Medical Systems, Inc. (INSP)vs › | $1.99B | 14.92 | 29.48 | 184.64 | 184.64 |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.02B | 6.87 | 15.39 | 40.25 | 40.25 |
| Progyny, Inc. (PGNY)vs › | $2.04B | 28.28 | 33.84 | 41.30 | 55.21 |
| AxoGen, Inc. (AXGN)vs › | $1.95B | N/A | 1.02 | 1.02 | 39.76 |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.05B | N/A | 7.63 | 7.63 | 7.63 |
| Fortrea Holdings Inc. (FTRE)vs › | $2.06B | N/A | 34.42 | 34.42 | 34.42 |
| Alvotech (ALVO)vs › | $2.06B | N/A | 33.55 | 33.55 | 33.55 |
| Immunome, Inc. (IMNM)vs › | $1.93B | N/A | N/A | N/A | N/A |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.09B | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$22.71
Forward EPS (Est.)
$-4.49
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
